CHRS.OQ
Latest Trade
18.15USDChange
0.58(+3.30%)Volume
320,071Today's Range
-
18.5752 Week Range
-
23.88As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 17.57 |
|---|---|
Open | 17.75 |
Volume | 320,071 |
3M AVG Volume | 25.05 |
Today's High | 18.57 |
Today's Low | 17.65 |
52 Week High | 23.88 |
52 Week Low | 8.34 |
Shares Out (MIL) | 70.13 |
Market Cap (MIL) | 1,232.17 |
Forward P/E | 12.30 |
Dividend (Yield %) | -- |
KKR Biosimilar Reports 5.6% Stake In Coherus Biosciences As Of Nov. 29
Coherus BioSciences Reports Q3 Earnings Per Share Of $0.63
Coherus BioSciences Acquires Commercial Rights For Leading Lucentis Biosimilar In The United States
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
Industry
Biotechnology & Drugs
Executive Leadership
Dennis M. Lanfear
Chairman of the Board, President, Chief Executive Officer
Jean-Frederic Viret
Chief Financial Officer
Vincent R. Anicetti
Chief Operating Officer
Peter K. Watler
Chief Technology Officer
Vladimir Vexler
Chief Scientific Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 5.31 |
Price To Book (MRQ) | 21.98 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 317.32 |
LT Debt To Equity (MRQ) | 317.32 |
Return on Investment (TTM) | -6.63 |
Return on Equity (TTM) | -5.11 |
Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.
* SAYS PUBLIC OFFERING OF 5.17 MILLION COMMON SHARES PRICED AT $14.50PER SHARE Source text for Eikon: Further company coverage:
* COHERUS BIOSCIENCES INC SAYS COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $75,000,000 OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:
* COHERUS BIOSCIENCES RE-SUBMITS BIOLOGICS LICENSE APPLICATION FOR CHS-1701 (PEGFILGRASTIM BIOSIMILAR CANDIDATE)
* COHERUS BIOSCIENCES-U.S. COURT ADOPTED MAGISTRATE JUDGE BURKE'S REPORT & RECOMMENDATION TO GRANT MOTION OF CO TO DISMISS PATENT INFRINGEMENT COMPLAINT
* COHERUS BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
* COHERUS BIOSCIENCES SAYS HAD CASH AND CASH EQUIVALENTS OF ABOUT $126.9 MILLION AS OF DEC 31 - SEC FILING Source text : (http://bit.ly/2qqVZLs) Further company coverage:
* COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM
* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares
* Coherus Biosciences reports third quarter 2017 operating and financial results
* Coherus Biosciences Inc - Files for offering of upto 6.56 million shares of common stock by the selling stockholder - SEC filing Source text: (http://bit.ly/2xYarNR) Further company coverage:
* Temasek Holdings (private) Ltd reports 11.32 pct passive stake in Coherus Biosciences Inc as of Aug 24 - sec filing Source text - http://bit.ly/2esXsfi Further company coverage:
* Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects
* Coherus Biosciences Inc - Temasek plans to invest up to $150 million over two tranches
* Anticipate resubmitting BLA in U.S. At end of Q4 of 2017 for CHS-1701
* Says commenced and completed, a restructuring plan to reduce operating costs and better align its workforce
* Coherus Biosciences - determined it is prudent to put into place alternative fill & finish vendor to support co's adalimumab biosimilar candidate chs-1420's bla filing
Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients.
* Coherus BioSciences Inc says the agency can take up to 6 months to evaluate the requested information
Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) denied the approval of its biosimilar for Amgen Inc's blockbuster treatment, Neulasta, which fights infections in cancer patients.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.